Ambuja Cements, Jet Airways, Just Dial among top 10 stocks

Stocks that likely to be in limelight are:Ambuja Cements has posted a net profit of Rs 153.57 crore in the July-September quarter, down 35.8 percent from Rs 239.06 crore, year-on-year. The company's total income came in at Rs 2,110.90 crore, down 4.2 percent from Rs 2202.06 crore.A CNBC-TV18 poll had forecast the firm to post profit of Rs 185 crore on revenues of Rs 2,180 crore.The company's earnings before interest, taxes, depreciation and amortization came in at Rs 310 crore, down 21.1 percent from Rs 393 crore (estimates: Rs 332 crore), leading to a lower than expected margin of 14.7 percent (poll: 15.2 percent).The cement market was subdued during the quarter, the company said, which led to net sales, as higher volumes (up 3.2 percent) were offset by lower realizations (down 6.9 percent)."Lower operating costs with improved operational efficiencies partly mitigated the impact of reduced sales realization," the company said, adding that it took a provision of Rs 40 crore towards district mineral fund, as outlined in the new MMDR Act. "This impacted EBITDA margin for the quarter by 130 basis points."The company also said that its chief financial officer, Sanjeev Churiwala, had resigned and said it was looking for a successor.Private carrier Jet Airways posted a consolidated net profit of Rs 83 crore in the second quarter of this fiscal, ended September 30, against a net loss of Rs 42.8 crore a year-ago period, helped by healthy 26.3 percent growth in passenger traffic coupled with improved aircraft utilisation by the airline.The total sales grew by 8.1 percent to Rs 5,504 crore in the July-September quarter of the current fiscal as compared to Rs 5,092 crore in Q2FY15, the company said in a release. Jet Airways carried a total of 6.37 million passengers in the quarter, an increase of 26.3 percent from 5.04 million passengers flown by the airline in the corresponding quarter of the previous fiscal, it said, adding average aircraft utilisation also grew by 9.9 percent to 12.6 hours during this period.Just Dial reported mixed second quarter in FY16 year on year. Revenue rises by 19.6 percent at Rs 171.27 crore versus Rs 143.13 crore. EBITDA at Rs 39.72 crore versus Rs 42.6 crore. EBITDA Margin at 23.2 percent versus 28.9 percent. Profit After Tax up by 47.5 percent at Rs 46.31 crore versus Rs 31.49 crore. Profit supported by higher Other Income of Rs 26.26 crore. Revenue in Q2FY15 inadvertently included deferred revenue of Rs 4.27 crore. Hence reported revenue growth is 16.2 percent. Adjusted EBITDA for ESOP at 27.4 percent versus 31 percent. Paid campaigns at 3,49,800; Year on Year, growth of 18.1 percent.Monnet Ispat to mull raising equity via conversion of loan into equity shares to lenders under SDR. Monnet Ispat board Meet On November 2. To convert unsecured loan in equity shares. Pidilite sees a good second quarter in FY16 year on year. Revenue in-line; Big beat on margins. Correction in crude-linked input cost boosts margins. Revenue up by 5.2 percent at Rs 1,320 crore versus Rs 1,255 crore. EBITDA Margin at 22.9 percent versus 16.5 percent.Net Profit rises by 38 percent at Rs 192 crore versus Rs 139 crore. Steady growth in Consumer Bazaar products. Massive improvement in industrial product margins. JK Tyre & Industries posted 54.7 percent rise in its consolidated net profit at Rs 118.27 crore for the second quarter ended September 30. The company had posted a net profit of Rs 76.45 crore during the same period of previous fiscal.Net sales of the company, however, declined to Rs 1,790.91 crore from Rs 1,858.68 crore during the same period of previous fiscal, JK Tyre & Industries said in a statement.
Drug major Sun Pharma is recalling over ten lakh boxes of its anti-allergic Loratadine drug from the US market as the lot was found to be 'super potent' and 'out of specification'. As per the information available on the USFDA website, Ohm Laboratories Inc, a unit of Ranbaxy Laboratories, which the company acquired last year, is recalling 10,85,095 boxes for being "Superpotent Drug: Out Of Specification". Sun Pharma had acquired Ranbaxy in a USD 4 billion deal last year making it the largest Indian pharma company by sales.

The recall was initiated on July 28 this year and has been put under Class-III which FDA defined as "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences". Comments from the company could not be obtained immediately. Loratadine is an antihistamine and is used to treat the symptoms of allergies, such as sneezing, watery eyes, and runny nose. Strides and Shasun Pharma gets fipb approval for merger. Quarterly results henceforth will be of the combined entity. Excel Crop care sees weak quarter in FY16 year on year. Net Profit down by 35 percent at Rs 18.6 crore. Total Income falls by 18 percent at Rs 245.1 crore.EBIDTA down  by 29 percent at Rs 28.3 crore. EBIDTA Margin at 11.5 percent versus 13.3 percent.The other stocks in focus are HDFC and Infosys.